Disposition · Activity not yet classified
Catalyst Clinical Research
Transaction overview
Announced
Exact closing date not established.
On January 20, 2026, Worldwide Clinical Trials announced a definitive agreement to acquire Catalyst Clinical Research, a portfolio company of QHP Capital, L.P. QHP reposted the announcement on March 6, 2026. Completion was expected in the first quarter of 2026, subject to closing conditions; these sources do not establish completion or an exact closing day.
Selected source-supported transactions; coverage is incomplete. Announcements do not establish completion or that a deal is still pending. Sponsor activity and operating-business transactions are distinct from adviser acquisitions. Unclassified activity is excluded from adviser-only counts.
Source evidence
- Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research ↗
Official firm website · Published Mar 6, 2026
QHP published this repost on March 6, 2026. Its body describes the same conditional acquisition of Catalyst Clinical Research, a QHP Capital, L.P. portfolio company, with expected first-quarter 2026 completion. It does not establish a new March 6 announcement or completion.
- Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research ↗
Kohlberg · Published Jan 20, 2026
The January 20, 2026 body dateline identifies the earlier announcement of the same conditional Catalyst acquisition and names QHP Capital, L.P. as the target sponsor.